In addition, since patients with severe brain trauma have a considerable risk of deep venous thrombosis (For the EPO-TBI investigators and the ANZICS Clinical Trials Group et al., 2017), the use of TXA may break the balance mechanism of anticoagulation and fibrinolysis, which may lead to poor prognosis. The gene discussed is EPO; the disease is brain injury.